ArticleHaematologica2025

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.

Tycel Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.